Related Experiment Videos

[Triple oral therapy in type 2 diabetes]

A J Scheen1

  • 1Département de médecine, CHU Sart Tilman, 4000 Liège I, Belgique. andre.scheen@chu.ulg.ac.be

Revue Medicale Suisse
|October 5, 2005
PubMed

Insights

Triple oral therapy effectively targets the three main issues in type 2 diabetes: impaired insulin secretion, excess liver glucose production, and poor muscle glucose uptake. Clinical trials confirm its safety and efficacy, though its optimal role in diabetes management requires further definition.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology

Context:

  • Type 2 diabetes involves pancreatic beta-cell dysfunction, hepatic insulin resistance, and impaired skeletal muscle glucose uptake.
  • Current treatments often target individual pathophysiological defects.
  • The combination of agents addressing these core defects offers a potential therapeutic strategy.

Purpose:

  • To evaluate the efficacy and safety of a triple oral therapy for type 2 diabetes.
  • To explore the potential role of simultaneously targeting insulin secretion, hepatic glucose production, and insulin-mediated glucose uptake.

Summary:

  • Type 2 diabetes pathophysiology is characterized by defects in insulin secretion, increased hepatic glucose production, and reduced skeletal muscle glucose uptake.
  • Each defect can be addressed by specific drug classes: insulin secretagogues (sulfonylureas, glinides), metformin, and thiazolidinediones (glitazones).
  • Triple oral therapy combines these agents to simultaneously target the main metabolic abnormalities, showing promising efficacy and safety in recent trials.

Impact:

  • Triple oral therapy presents a viable option for managing type 2 diabetes by addressing its multifaceted nature.
  • Further research is needed to define the precise positioning of this combination therapy within the broader treatment landscape.
  • This approach may offer improved glycemic control for patients with type 2 diabetes.

Related Concept Videos

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...